|
Dec. 1996
|
Foundation of CF Pharma Ltd.
|
|
Oct. 1998
|
First reaction in the R&D Laboratory
|
|
Dec. 1999
|
Plant production starts
|
|
May. 2000
|
First Capital increase by H. Lundbeck A/S, Denmark
|
|
Jun. 2001
|
Second capital increase by H. Lundbeck A/S, Denmark
|
|
Oct. 2002
|
Third capital increase, 47% share owned by H. Lundbeck A/S, Denmark
|
|
Feb. 2003
|
Final production area constructed
|
|
May. 2003
|
Successful inspection by NIP*
License for manufacturing APIs
GMP Certificate for Lamotrigine
|
|
Jun. 2004
|
Successful inspection by NIP*
GMP Certificate for Atracurium besylate and Bicalutamide
License for manufacturing psychotropics
|
|
Jun. 2004
|
License for manufacturing psychotropics
|
|
Oct. 2004
|
Successful inspection by NIP*
License for release of Drugs from non-EU countries
|
|
2004
|
Marketing Authorization for drugs made of Lamotrigine
|
|
2005
|
DMF submission to FDA (Atracurium, Bicalutamide, Lamotrigine)
|
|
2008
|
Successful inspection by NIP*
|
*NIP: National Institute of Pharmacy